Marc de Garidel, CinCor Pharma CEO (Eric Piermont/AFP via Getty Images)

How the price of As­traZeneca's buy­out of Cin­Cor fell by $1.4B

Cin­Cor scored a $1.8 bil­lion buy­out deal with As­traZeneca ear­li­er this month, but ac­cord­ing to re­cent­ly re­leased doc­u­ments, it al­most walked away from the deal ta­ble with much more than that.

In Sep­tem­ber, As­traZeneca of­fered to buy Cin­Cor for $60 per share plus a con­tin­gent val­ue right of $6 per share, adding up to $3.2 bil­lion if all mile­stones had been achieved, ac­cord­ing to an SEC fil­ing pub­lished on Mon­day. How­ev­er, the Cin­Cor board and CEO Marc de Garidel want­ed to see more cash up­front.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.